药物性肝损伤临床与组织病理学特点

doi:10.3969/j.issn.1672-5069.2019.02.003

Abstract

Liu Liwei, Zhao Xinyan. Clinicopathological features of drug-induced liver injury[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 160-163.

[1] Alempijevic T,Zec S,Milosavljevic T.Drug-induced liver injury:Do we know everything World [J] Hepatol,2017,9(10):491-502.
[2] Yu Y,Mao Y,Chen C,et al.CSH guidelines for the diagnosis and treatment of drug-induced liver injury. Hepatol Int,2017,11(3):221-241.
[3] Church R J,Kullak-Ublick G A,Aubrecht J,et al. Candidate biomarkers for the diagnosis and prognosis of drug-induced liver injury:An international collaborative effort. Hepatology (Baltimore,Md.),2018[ahead of print].
[4] Kullak-Ublick G A,Andrade R J,Merz M,et al. Drug-induced liver injury:recent advances in diagnosis and risk assessment. Gut,2017,66(6):1154-1164.
[5] Chalasani N P,Hayashi P H,Bonkovsky H L,et al.ACG Clinical Guideline:the diagnosis and management of idiosyncratic drug-induced liver injury. Am J Gastroenterol,2014,109(7):950-966,967.
[6] Fontana R J,Seeff L B,Andrade R J,et al.Standardization of nomenclature and causality assessment in drug-induced liver injury:summary of a clinical research workshop. Hepatology,2010,52(2):730-742.
[7] 杨瑞园,赵新颜. 肝组织病理学检查在药物性肝损伤诊治中的意义. 临床肝胆病杂志,2018,34(6):1172-1175.
[8] Brewer C T,Chen T.Hepatotoxicity of herbal supplements mediated by modulation of cytochrome P450. Int J Mol Sci,2017,18(11):1423-1427.
[9] Benichou C.Criteria of drug-induced liver disorders. Report of an international consensus meeting. J Hepatol,1990,11(2):272-276.
[10] Sundaram V,Bjornsson E S.Drug-induced cholestasis. Hepatol Commun,2017,1(8):726-735.
[11] Bjornsson E S,Jonasson J G.Drug-induced cholestasis. Clin Liver Dis,2013,17(2):191-209.
[12] Popper HRE,Cardiol D.Drug-induced liver disease:A penalty for progress. Arch Intern Med,1965,115:128-136.
[13] Kleiner D E,Chalasani N P,Lee W M,et al.Hepatic histological findings in suspected drug-induced liver injury: systematic evaluation and clinical associations. Hepatology (Baltimore,Md.),2014,59(2):661-670.
[14] Kleiner D E.Recent advances in the histopathology of drug-induced liver injury. Surg Pathol Clin,2018,11(2):297-311.
[15] Kleiner D E.The histopathological evaluation of drug-induced liver injury. Histopathology,2017,70(1):81-93.
[16] Zimmerman H J.The spectrum of hepatotoxicity. Perspect Biol Med,1968,12(1):135-161.
[17] 于乐成,茅益民,陈成伟. 药物性肝损伤诊治指南. 实用肝脏病杂志,2017,20(2):257-274.
[18] Newsome P N,Hussain M A,Theise N D.Hepatic oval cells: helping redefine a paradigm in stem cell biology. Curr Top Dev Biol,2004,61:1-28.
[19] Than N N,Newsome P N.Stem cells for liver regeneration. QJM Mon J Assoc Phys,2014,107(6):417-421.
[20] Sebode M,Schulz L,Lohse A W.“Autoimmune(-Like)” drug and herb induced liver injury:New insights into molecular pathogenesis. Int J Mol Sci,2017,18(9):842-846.
[21] de Boer Y S,Kosinski A S,Urban T J,et al. Features of autoimmune hepatitis in patients with drug-induced liver injury. Clin Gastroenterol Hepatol,2017,15(1):103-112.
[22] Bjornsson E,Talwalkar J,Treeprasertsuk S,et al.Drug-induced autoimmune hepatitis:clinical characteristics and prognosis. Hepatology (Baltimore,Md.),2010,51(6):2040-2048.
[23] 中华医学会肝病学分会,中华医学会消化病学分会,中华医学会感染病学分会. 自身免疫性肝炎诊断和治疗共识(2015). 临床肝胆病杂志,2016,32(1):9-22.
[24] Suzuki A,Brunt E M,Kleiner D E,et al.The use of liver biopsy evaluation in discrimination of idiopathic autoimmune hepatitis versus drug-induced liver injury. Hepatology,2011,54(3):931-939.
[25] Reau N S,Jensen D M.Vanishing bile duct syndrome. Clin Liver Dis,2008,12(1):203-217.
[26] Moradpour D,Altorfer J,Flury R,et al.Chlorpromazine-induced vanishing bile duct syndrome leading to biliary cirrhosis. Hepatology,1994,20(6):1437-1441.
[27] Geubel A P,Sempoux C L.Drug and toxin-induced bile duct disorders. J Gastroenterol Hepatol,2000,15(11):1232-1238.
[28] Desmet V J.Vanishing bile duct syndrome in drug-induced liver disease. J Hepatol,1997,26(Suppl 1):31-35.
[29] Kleiner D E.Drug-induced liver injury:The hepatic pathologist's approach. Gastroenterol Clin North Am,2017,46(2):273-296.
[30] Bonkovsky H L,Kleiner D E,Gu J,et al.Clinical presentations and outcomes of bile duct loss caused by drugs and herbal and dietary supplements. Hepatology,2017,65(4):1267-1277.
[31] Navarro V J,Khan I,Bjornsson E,et al.Liver injury from herbal and dietary supplements. Hepatology (Baltimore,Md.),2017,65(1):363-373.
[32] Medina-Caliz I,Garcia-Cortes M,Gonzalez-Jimenez A,et al.Herbal and dietary supplement-induced liver injuries in the spanish DILI registry. Clin Gastroenterol Hepatol,2018,16(9):1495-1502.
[33] Wang Y,Wang L,Saxena R,et al. Clinicopathological features of He Shou Wu-induced liver injury:This ancient anti-aging therapy is not liver-friendly. Liver Int,2018[ahead of print].

Clinicopathological features of drug-induced liver injury

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Min Feng, Huang Wenqi, Wu Weibing, et al.. Implications of serum adipocytokine levels in patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(6): 824-827.
[2]	Zhang Mei, Shi Xiuying, Li Linjuan, et al. Hepatic expression of interferon inducible protein -10 in patients with hepatitis B liver cirrhosis and hepatogenic diabetes mellitus [J]. Journal of Practical Hepatology, 2019, 22(5): 688-691.
[3]	Wang Gang, Zhao Hongbo, Zhu Yaling, et al. Cancerous XPO5 gene level in patients with hepatocellular carcinoma and its clinical significance [J]. Journal of Practical Hepatology, 2019, 22(5): 724-727.
[4]	Lin Lan, Shen Min, Ruan Jianwen.. Expression of programmed death receptor 1 in liver tissue of patients with autoimmune hepatitis and its clinical implications [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 204-207.
[5]	Huang Chunyang, Shan Jing, Liao Huiyu, Huang Yunli, Han Ying, Zhang Xiaodan, Du Xiaofei, Ren Meixin, Bian Xinqu, Liu Yanmin. Clinical and laboratory characteristics of patients with drug-induced liver injury receiving glucocorticoid therapy [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 208-211.
[6]	Wu Xiuxin, Zhang Huiyong, Zhang Kai. Changes of plasma microRNA-4284 in patients with anti-tuberculosis drug-induced hepatotoxicity [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 212-215.
[7]	Wang Huming, Fan Dongsheng, Xu Jie, Liu Xianfegn, Zhou Ning, Li Min, Bao Nana. Cancerous miRNA-30c levels affecting the survival of patients with hepatocellular carcinoma after hepatectomy [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 248-251.
[8]	Sun Wenjing, Chen Dongfeng.. Literature analysis about RUCAM scale and Maria scale in diagnosis of Chinese patients with drug-induced liver injury [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(6): 881-884.
[9]	Zhang Haitao, Sun Hao, Li Kai, et al.. Prevalence of Helicobacter pylori infection and gastric mucosa inflammation in patients with bile reflux gastritis [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(6): 967-970.
[10]	Zheng Zhenchuan, Xu Xihai.. Pathological and clinical features and factors affecting significant liver fibrosis in patients with chronic hepatitis B [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(5): 713-716.
[11]	Zhou Zhiling, Yin Qian.. Forecasting hepatic activity index and liver fibrosis staging by serum golgiprotein-73 levels in individuals with chronic hepatitis B viral carriers [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(5): 717-720.
[12]	Tong Xin, Fan Hua. Efficacy of bicyclic alcohol on liver function in gastric cancer patients with chemotherapy-induced liver injury [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(4): 625-626.
[13]	Liu Cong, Wang Tingting, Zuo Lili, et al. Analysis of patients with drug-induced liver injury in recent 3 years [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(4): 639-640.
[14]	Ji Yuan. Clinical and histopathological features of patients with idiopathoc noncirrhotic portal hypertension [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(3): 325-328.
[15]	Zhang Jinlian, Cai Zhaogen, Wu Qiong, et al. Serum and hepatic tissue microRNAlet-7 levels and its clinical implication in patients with hepatocellular carcinoma [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(3): 435-438.